Abstract
Ascomycin derivatives represent a novel class of anti-inflammatory macrolactams that are under development for the treatment of skin diseases. The main biological effect of ascomycins is a blockage of the synthesis of both Th1- and Th2-type cytokines in target cells. SDZ ASM 981 is the most advanced ascomycin derivative under development. It has high antiinflammatory activity in animal models of allergic contact dermatitis and does not induce skin atrophy. Topical application of SDZ ASM 981 has been shown to be effective in atopic dermatitis (AD) and allergic contact dermatitis. Clinical studies using semi-occlusive conditions have also shown effectiveness in psoriasis. SDZ ASM 981 holds promise in overcoming the drawbacks of topical corticosteroids and studies are ongoing to further investigate its efficacy and safety in the treatment of inflammatory skin diseases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
